Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTARA THERAPEUTICS, INC.

(TARA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
7.07(c) 7.15(c) 7.39(c) 7.08(c) 7.0589 Last
211 337 93 792 48 823 49 743 49 061 Volume
-1.81% +1.13% +3.36% -4.19% -0.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -50,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,70x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -80,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,52x
Yield 2022 -
Capitalization 79,5 M 79,5 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 27
Free-Float 81,0%
More Financials
Company
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase - Recombinant Human elastase. The Company's lead product pipeline is TARA 002 for the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on... 
More about the company
Ratings of Protara Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about PROTARA THERAPEUTICS, INC.
11/08Oppenheimer Adjusts Price Target on Protara Therapeutics to $34 from $32, Keeps Outperf..
MT
11/04PROTARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/04Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/04PROTARA THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/04Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overvi..
PU
10/25PROTARA THERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
10/18PROTARA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Fina..
AQ
10/18Protara Therapeutics, Inc. Announces Management Changes
CI
10/12PROTARA THERAPEUTICS : Thinking about buying stock in Protara Therapeutics, Standard Lithi..
PR
10/12Wall Street Set for Cautiously Higher Open, Earnings Season Eyed
MT
10/12PROTARA THERAPEUTICS : FDA Clears Protara's TARA-002 Trial in Non-Muscle Invasive Bladder ..
MT
10/12PROTARA THERAPEUTICS : FDA Clears IND Application for TARA-002 in Bladder Cancer
DJ
10/12PROTARA THERAPEUTICS : Announces FDA Clearance of Investigational New Drug Application for..
PU
10/12PROTARA THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements ..
AQ
10/12PROTARA THERAPEUTICS : Announces FDA Clearance of Investigational New Drug Application for..
AQ
More news
News in other languages on PROTARA THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on PROTARA THERAPEUTICS, INC.
More recommendations
Chart PROTARA THERAPEUTICS, INC.
Duration : Period :
Protara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 7,08 $
Average target price 40,50 $
Spread / Average Target 472%
EPS Revisions
Managers and Directors
Jesse Shefferman President, Chief Executive Officer & Director
Blaine T. Davis Chief Financial Officer & Secretary
Luke M. Beshar Chairman
Jacqueline Zummo Chief Scientific Operations Officer & Senior VP
Jathin Bandari Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
PROTARA THERAPEUTICS, INC.-70.76%80
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678